Raymond James Financial’s Prime Medicine PRME Stock Holding History
Bought
Maintained
Sold
Other funds holding PRME
Raymond James Financial's PRME Position: Q3 2026 in Review
Raymond James Financial increased its Prime Medicine (PRME) stake by 64% in Q3 2026, buying an estimated $61.7K and bringing the position to 47,754 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #5157.
Raymond James Financial first reported a position in PRME in Q2 2025 and has held it in 6 quarters since. The position peaked at $176K in Q3 2025. 186 funds tracked by Wall St. Rank hold PRME as of Q3 2026.
- Raymond James Financial held 47,754 shares of Prime Medicine worth $146K as of Q3 2026.
- Raymond James Financial bought 18,570 Prime Medicine shares in Q3 2026, an estimated $61.7K.
- Prime Medicine made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #5157 holding.
- Raymond James Financial first reported a position in Prime Medicine in Q2 2025 and has held it in 6 quarters since.
- Raymond James Financial's Prime Medicine position peaked at $176K in Q3 2025.
- 186 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.
Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.